Q3 T2Bmeet @ Boston 2026

Andrew Law brings more than 20 years of experience as a communications and public relations leader in the biopharmaceutical and life sciences industry. He is joining Sanofi following its acquisition of Blueprint Medicines, where he has held communications leadership roles since 2018. At Blueprint Medicines, Andrew spearheaded strategic portfolio communications from R&D programs to commercial medicines, and elevated visibility of the company as a fully integrated biopharmaceutical organization. In his corporate and portfolio communications roles, Andrew is responsible for translating Blueprint Medicines’ focus areas into accessible information that resonates with a diverse set of external stakeholders. Previously, Andrew held life sciences communications roles at Biogen and MSLGroup, a global PR agency owned by the Public Groupe. In 2002, he graduated from Haverford College with a B.S. degree in Chemistry.

Gretchen Murphy is Senior Director of Corporate and R&D Communications and Patient Advocacy at Alkermes, where she leads communications strategies that advance understanding of the company’s neuroscience portfolio. She is dedicated to ensuring patient experiences inform how the company listens, learns and communicates across its research and development efforts.

Prior to joining Alkermes in 2017, she held communications roles at Medidata and Chandler Chicco Companies. Gretchen holds a B.S. in Communications from Cornell University and an M.S. in Public Relations from Syracuse University’s S.I. Newhouse School of Public Communications.

Carlo Tanzi, Ph.D., is Founder and Principal of Kendall Investor Relations, a biotech-focused firm advising private and public companies on investor strategy, positioning, and execution across financings. He founded the firm in 2018.

Before founding Kendall IR, Carlo was Vice President of Investor Relations and Corporate Communications at Seres Therapeutics, where he served on the leadership team. Earlier, he spent nine years at Biogen in investor relations and program management roles, including Director of Investor Relations and Program Management Lead for Tecfidera and Tysabri. He began his career as a healthcare management consultant at Health Advances.

His IR experience spans multiple product launches, IPO and follow-on financings, clinical data readouts, R&D investor days, sell-side engagement, and investor targeting. He holds a Ph.D. in molecular biology from the University of Pennsylvania.

Alina is an experienced leader with a demonstrated history of merging complex science with fresh ideas within the bounds of healthcare compliance. Through her partnerships with leading pharmaceutical companies to small and midsize biotechs she has tackled scientific brand communications challenges across the product life cycle. From first-of-its-kind data to late-market entry and product maturation, Alina is masterful at narrating and visually showcasing a powerful story.